JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Share :
Published: 18 Sep 2026
Views: 272
Rating:
Save
Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

Prof Yi-Long Wu speaks to ecancer about a phase 2 study of JS207 plus chemotherapy in patients with unresectable stage III NSCLC.

JS207, a bispecific antibody targeting PD-1 and VEGF, combined with platinum-based chemotherapy shows encouraging activity in patients with unresectable stage III NSCLC.

In this phase II study, 22 of 42 patients underwent surgery following neoadjuvant treatment, with a pathological complete response rate of 54.5% and a major pathological response rate of 72.7%.

Prof Wu further covers the safety profile of the combination. He notes that anaemia and reductions in neutrophil and white blood cell counts among the most common adverse events.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
31 May 2026

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management? ( Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium )
11 May 2026

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )
23 Apr 2026

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer ( Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA )
15 Apr 2026

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer

Dr Eva-Lotte Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer ( Dr Eva-Lotte Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany )
15 Apr 2026

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer

Dr Saumil Gandhi - University of Texas MD Anderson Cancer Center, Houston, USA
Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer ( Dr Saumil Gandhi - University of Texas MD Anderson Cancer Center, Houston, USA )
15 Apr 2026

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC

Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC ( Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )
15 Apr 2026

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China
Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )
15 Apr 2026

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )
14 Apr 2026